RARA and acute promyelocytic leukemia: Therefore, GTF2I-RARA exhibited ATRA resistance via multiple aspects, and the proteasome inhibitor, MG132, partially reversed ATRA resistance and synergistically induced GTF2I-RARA-positive APL differentiation with ATRA [85].